Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly losses of $(1.50) per share which beat the analyst consensus estimate of $(1.57) by 4.46 percent. This is a 6.83 percent increase over losses of $(1.61) per share from the same period last year.
Morgan Stanley Downgrades First Quantum Minerals to Underweight, Lowers Price Target to C$23
Morgan Stanley analyst Ioannis Masvoulas downgrades First Quantum Minerals (TSX:FM) from Equal-Weight to Underweight and lowers the price target from C$27 to C$23.
